Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on invested capital (ROIC) high or low?
The return on invested capital (ROIC) of -54.45% is 26% below its 5-year average of -43.17%, around the middle of its 5-year range (-66.98%–-25.53%).
As of the fiscal period ended Tuesday, June 30, 2026. 31.99% below its 12-month average of -41.25%.
Trailing-twelve-month return on invested capital at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -54.45%.
RETURN ON INVESTED CAPITAL (ROIC)
-54.45%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
-41.25%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
-41.94%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
-43.17%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
N/A
CURRENT VS TTM AVG
-31.99%
CURRENT VS 3Y AVG
-29.83%
CURRENT VS 5Y AVG
-26.14%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-35.64%
median of 838 covered companies
CURRENT VS SECTOR MEDIAN
-52.76%
vs the sector median at left
Neurogene Inc.
Market Cap
$402.92M
Return on Invested Capital (ROIC)
-54.45%
TTM Avg
-41.25%
3Y Avg
-41.94%
5Y Avg
-43.17%
Market Cap
$437.74M
Return on Invested Capital (ROIC)
N/A
TTM Avg
-32.80%
3Y Avg
-24.38%
5Y Avg
-16.55%
Market Cap
$399.35M
Return on Invested Capital (ROIC)
-36.54%
TTM Avg
-40.95%
3Y Avg
-100.88%
5Y Avg
-100.88%
Market Cap
$403.77M
Return on Invested Capital (ROIC)
-19.13%
TTM Avg
-11.02%
3Y Avg
-12.07%
5Y Avg
-13.96%
Market Cap
$405.74M
Return on Invested Capital (ROIC)
-89.93%
TTM Avg
-54.36%
3Y Avg
-39.52%
5Y Avg
-23.86%
Market Cap
$399.83M
Return on Invested Capital (ROIC)
-25.26%
TTM Avg
-29.12%
3Y Avg
-26.65%
5Y Avg
-26.65%
Market Cap
$409.29M
Return on Invested Capital (ROIC)
-46.16%
TTM Avg
-62.80%
3Y Avg
-62.80%
5Y Avg
-62.80%
Market Cap
$411.43M
Return on Invested Capital (ROIC)
-7.11%
TTM Avg
-10.90%
3Y Avg
-16.50%
5Y Avg
-14.69%
Market Cap
$409.39M
Return on Invested Capital (ROIC)
-81.80%
TTM Avg
-65.32%
3Y Avg
-58.77%
5Y Avg
-53.22%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Neurogene Inc. (NGNE) | $402.92M | -54.45% | -41.25% | -41.94% | -43.17% |
| YD Bio Limited Ordinary Shares (YDES)vs › | $437.74M | N/A | -32.80% | -24.38% | -16.55% |
| Carlsmed, Inc. (CARL)vs › | $399.35M | -36.54% | -40.95% | -100.88% | -100.88% |
| Myriad Genetics, Inc. (MYGN)vs › | $403.77M | -19.13% | -11.02% | -12.07% | -13.96% |
| Atea Pharmaceuticals, Inc. (AVIR)vs › | $405.74M | -89.93% | -54.36% | -39.52% | -23.86% |
| Shoulder Innovations, Inc. (SI)vs › | $399.83M | -25.26% | -29.12% | -26.65% | -26.65% |
| Eikon Therapeutics, Inc. Common Stock (EIKN)vs › | $409.29M | -46.16% | -62.80% | -62.80% | -62.80% |
| Strata Critical Medical, Inc. (SRTA)vs › | $411.43M | -7.11% | -10.90% | -16.50% | -14.69% |
| Rezolute, Inc. (RZLT)vs › | $409.39M | -81.80% | -65.32% | -58.77% | -53.22% |
| MapLight Therapeutics, Inc. (MPLT)vs › | $412.91M | -69.35% | -52.27% | -73.46% | -73.46% |
ROIC
-54.4%
ROE
-51.2%
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2026-06-30 | -54.45% |
| 2026-03-31 | -44.78% |
| 2025-12-31 | -37.46% |
| 2025-09-30 | -35.63% |
| 2025-06-30 | -33.95% |
| 2025-03-31 | -29.80% |
| 2024-12-31 | -25.53% |
| 2024-09-30 | -51.12% |
| 2024-06-30 | -40.61% |
| 2024-03-31 | -32.93% |
| 2023-12-31 | -27.85% |
| 2023-09-30 | -64.12% |
| 2023-06-30 | -66.98% |
| 2023-03-31 | -60.36% |
| 2022-12-31 | -57.00% |
| 2022-09-30 | -50.47% |
| 2022-06-30 | -47.90% |
| 2022-03-31 | -42.80% |
| 2021-12-31 | -38.95% |
| 2021-09-30 | -34.59% |
| 2021-06-30 | -29.23% |
| 2021-03-31 | -24.60% |
| 2020-12-31 | -20.44% |
| 2020-09-30 | -17.52% |
| 2020-06-30 | -27.78% |
| 2020-03-31 | -21.04% |
| 2019-12-31 | -17.11% |
| 2019-09-30 | -30.36% |
| 2019-06-30 | -21.41% |
| 2019-03-31 | -15.13% |
| 2018-12-31 | -32.23% |
| 2018-09-30 | -46.40% |
| 2018-06-30 | -45.16% |
| 2018-03-31 | -66.78% |
| 2017-12-31 | -51.44% |
| 2017-09-30 | -40.18% |
| 2017-06-30 | -33.77% |
